- Company
- Reimb discussions discontinued for NMOSD drug Uplizna
- by Eo, Yun-Ho Nov 7, 2024 05:47am
- Uplizna, a new drug for neuromyelitis optica spectrum disorder (NMOSD) that is administered twice a year, has failed to pass the final gateway to reimbursement in Korea. According to Dailypharm coverage, Mitsubishi Tanabe Pharma Korea’s pricing negotiations with the National Health Insurance Service (NHIS) for Uplizna (inebilizumab), a t
- Company
- 20-valent pneumococcal conjugate vaccine set to launch
- by Moon, sung-ho Nov 6, 2024 05:52am
- Attention has been drawn to another competitor set to launch in the market for the 'pneumococcal vaccine.' This year, the pneumococcal vaccine market has been fiercely competitive with newly released products. As the 20-valent vaccine is likely to come out right after the 15-valent conjugate vaccine has entered the market after 13 years, comp
- Company
- Roche seeks digital solutions for its healthcare ecosystem
- by Whang, byung-woo Nov 6, 2024 05:52am
- With the importance of personalized healthcare being emphasized more than ever with the emergence of innovative new drugs, Roche Diagnostics Korea is aiming to lead the market by focusing on digital solutions. The company plans to lead the healthcare sector through digital transformation in line with the paradigm shift in treatment, from earl
- Company
- CKD’s CKD-508 receives approval to initiate P1T in the U.S.
- by Son, Hyung Min Nov 6, 2024 05:52am
- Chong Kun Dang announced on the 4th that it has received approval from the U.S. Food and Drug Administration (FDA) for the Phase I clinical trial of CKD-508, its new drug candidate for dyslipidemia. In the trial, Chong Kun Dang will confirm the safety and lipid-improving effects of CKD-508 and explore the optimal dose for a Phase II trial
- Company
- Amgen's Prolia·Evenity generate KRW 2T in quarterly sales
- by Son, Hyung Min Nov 6, 2024 05:52am
- Amgen's Prolia and Evenity for the treatment of osteoporosis continue to show sales growth. Prolia and Evenity led Amgen's performance, generating sales of KRW 2 trillion in Q3. Analysis suggests that sequential therapy, using Evenity followed by Prolia for the treatment of osteoporosis with high-risk fractures, has been widely used, and it
- Company
- Chong Kun Dang speeds up dyslipidemia drug development
- by Son, Hyung Min Nov 5, 2024 05:46am
- &160; Chong Kun Dang is accelerating the development of new drugs for dyslipidemia. The company has received approval to initiate a second global clinical trial in 10 years for its new drug candidate 'CKD-508' since the company began its research in 2014. According to industry sources on the 4th, Chong Kun Dang recently received approva
- Company
- ‘Prevent MI recurrence through efficient LDL-C control'
- by Whang, byung-woo Nov 5, 2024 05:45am
- With the rise of metabolic diseases such as hypertension, diabetes, and hyperlipidemia increase in Korea, the prevalence of myocardial infarction and atherosclerotic cardiovascular diseases are also on the rise. The mortality rate of myocardial infarction is in the 20-30% range when it occurs for the first time, but the mortality rate increas
- Company
- New oHCM drug 'Camzyos' nearing approval for reimb in KOR
- by Eo, Yun-Ho Nov 5, 2024 05:45am
- 'Camzyos,' a new drug to treat obstructive hypertrophic cardiomyopathy (oHCM), is nearing 90% approval for insurance reimbursement listing. Sources said that BMS Pharmaceutical Korea and the National Health Insurance Service (NHIS) concluded drug pricing negotiations for Camzyos (mavacamten), a new drug for obstructive hypertrophic cardi
- Company
- 'Nabota' generated KRW 115.8B over 9 mths in foreign mkt
- by Chon, Seung-Hyun Nov 5, 2024 05:45am
- Daewoong's Nabota, which contains botulinum toxin, is expanding its presence in the foreign market. Its export amount surpassed KRW 100 billion up to Q3 2024. Over 80% of the overall sales were accounted for by sales generated in the foreign market. It is a cash cow export product. According to Daewoong on November 2, Nabota generated sales o
- Company
- 'SGLT2·DPP4' comb market records robust growth
- by Kim, Jin-Gu Nov 4, 2024 05:48am
- The market for combination drugs containing SGLT-2 inhibitor and DPP-4 inhibitor for treating type 2 diabetes is showing rapid growth. The industry expects the market size to expand by over KRW 30 billion this year. Products containing one or more original active ingredients are leading the market growth. Boehringer Ingelheim's 'Esglite
